March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the Strength of Unprecedented Results from the Positive Phase…
The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.Expanded collaboration…
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and…
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum…
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal government’s Countermeasures Injury Compensation Program (CICP) has approved…
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc., a clinical-stage biotech company pioneering the future of…
AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient Study has been seen by millions following its…
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the…
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…